17 of 100
17. Alexion Pharmaceuticals
Alexion Pharmaceuticals

3-year average
Revenue Growth: 43%
Profit Growth: 34%
Total Return: 69%

This biopharmaceutical company is focused on treating two severe and ultra-rare disorders. Its lead product, Soliris, is the only drug approved for patients with an extremely rare and life-threatening blood disease referred to as PNH (paroxysmal nocturnal hemoglobinuria). Alexion reported $274 million worth of second-quarter sales of Soliris, up 48% from the same period last year. The company credited the growth to increasing numbers of patients being treated with the drug globally. It follows Soliris's approval in the U.S. and European Union late last year as the first and only treatment for patients with an ultra-rare genetic disease known as Atypical Hemolytic Uremic Syndrome (aHUS). -- N.S.

Get stock quote: ALXN
Revenue ($ millions): $862
Net Income ($ millions): $194
Sectors: Health Care
What businesses do you think are primed to grow in this economy?
From the September 24, 2012 issue.

Northern Oil and Gas 237%
ZAGG 104%
Green Mountain Coffee Roasters 78%
Cirrus Logic 450%
HFF 341%
Questcor Pharmaceuticals 120%
3D Systems 112%
TPC Group 111%
To qualify, a company -- domestic or foreign -- must be trading on a major U.S. stock exchange; file quarterly reports to the SEC; have a minimum market... More
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2018 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2018. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or its affiliates.